Fundraising Fox
/Companies
Sign in

Junevity

Founded 2023 · 13 employees on LinkedIn · 2 known investors

Find your way into Junevity

Sign up to see every warm intro you have to Junevity

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Junevity team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.

AI & Machine LearningBiotechDeep TechLongevity

Founders & leadership

Junevity was founded in 2023 by John Hoekman, Janine Sengstack, Rob Cahill, and Hao Li.

JHJohn Hoekman
John HoekmanPhD, Co-founder & CEOPreviously spent 15 years at Impel NeuroPharma, which he co-founded in 2008, serving as Chief Scientific Officer and board director, interim CEO from 2016 to 2017, and Chief Technology and Development Officer through 2023. He joined Junevity in 2024, initially as Chief Scientific Officer.
JSJanine Sengstack
Janine SengstackPhD, Co-founder & CSOJanine Sengstack is co-founder and chief scientific officer of Junevity, a biotech company developing siRNA therapeutics for age-related diseases. She completed her PhD at UC San Francisco, where she worked with Dr. Hao Li on identifying genes associated with cellular aging and developed high-throughput methods for target discovery and validation.
RCRob Cahill
Rob CahillCo-founder, COO & CBORob Cahill is co-founder and COO/CBO of Junevity, a biotech company developing siRNA therapeutics for age-related diseases that launched from UCSF in 2023.
HLHao Li
Hao LiPhD, Co-founder of Junevity & UCSF ProfessorHao Li is a professor of biology at UCSF and director of the Hillblom Center for Biology of Aging, with a Ph.D. in theoretical physics from MIT. His research centers on aging mechanisms, systems biology, and human genetics, and he co-founded Junevity to develop siRNA-based therapeutics targeting age-related diseases.

Investors · 2

Type One Ventureslisted by Type One VenturesLos Angeles · $100K – $5M

How we know: Type One Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

$20M disclosed across 1 of 4 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Junevity went on to found or lead other companies.

John D. HoekmanPhD, Co-founder & CEOFounded Impelpharma +1Rob CahillCo-founder, COO & CBOFounded Sunrun

Related companies · 2

RevvityRevvity develops and sells reagents, instruments, software, and services for life sciences research and clinical diagnostics, serving pharmaceutical, biotech, academic and government institutions across drug discovery, development, and disease diagnosis workflows.
BionityBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.

Companies working in the same space as Junevity.

In the news

Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNAfinance.yahoo.com · Dec 2025Junevity Raises $10M; Expands Seed Funding to $20Mfinsmes.com · Dec 2025Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA - BioSpacebiospace.com · Dec 2025PRESS RELEASE — Junevity – Cell Reset for Longevityjunevity.com · Feb 2025Junevity Raises $10M in Seed Fundingfinsmes.com · Feb 2025

Frequently asked questions

What does Junevity do?
Junevity is a biotech company developing siRNA therapeutics based on its RESET platform, which uses transcription factor repression to restore healthy gene expression and target age-related diseases. The company applies bioinformatics, machine learning, and cellular aging research to develop treatments for metabolism and aging-related conditions.
Who founded Junevity?
Junevity was founded by John Hoekman, Janine Sengstack, Rob Cahill, Hao Li in 2023.
Who are Junevity's investors?
Junevity's investors include Goldcrest Capital, Type One Ventures.
How much funding has Junevity raised?
Junevity has disclosed $20M raised across 1 of its 4 known rounds.